PIGINI, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.941
EU - Europa 4.442
AS - Asia 3.717
SA - Sud America 416
AF - Africa 139
Continente sconosciuto - Info sul continente non disponibili 39
OC - Oceania 25
Totale 18.719
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.600
CN - Cina 1.701
SG - Singapore 1.030
RU - Federazione Russa 1.020
DE - Germania 931
IT - Italia 609
BR - Brasile 353
UA - Ucraina 310
GB - Regno Unito 296
CA - Canada 292
VN - Vietnam 282
SE - Svezia 276
FI - Finlandia 264
FR - Francia 250
HK - Hong Kong 248
PL - Polonia 200
TR - Turchia 117
ZA - Sudafrica 103
KR - Corea 97
IN - India 70
IE - Irlanda 68
CZ - Repubblica Ceca 51
BE - Belgio 45
EU - Europa 35
JP - Giappone 32
MX - Messico 32
NL - Olanda 29
AR - Argentina 27
IR - Iran 26
AU - Australia 23
ES - Italia 23
BD - Bangladesh 21
LT - Lituania 17
EC - Ecuador 14
IQ - Iraq 14
PK - Pakistan 12
RO - Romania 12
EG - Egitto 11
ID - Indonesia 9
MA - Marocco 8
RS - Serbia 7
AT - Austria 6
CO - Colombia 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
JO - Giordania 5
NP - Nepal 5
SA - Arabia Saudita 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CH - Svizzera 4
CL - Cile 4
HU - Ungheria 4
IL - Israele 4
JM - Giamaica 4
KE - Kenya 4
PE - Perù 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
BG - Bulgaria 3
GR - Grecia 3
KH - Cambogia 3
NI - Nicaragua 3
PA - Panama 3
PY - Paraguay 3
SN - Senegal 3
BY - Bielorussia 2
DK - Danimarca 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
UZ - Uzbekistan 2
AD - Andorra 1
BH - Bahrain 1
BO - Bolivia 1
BZ - Belize 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
LB - Libano 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
NG - Nigeria 1
PS - Palestinian Territory 1
PT - Portogallo 1
Totale 18.717
Salva come PNG Salva come JPEG
Città #
Dallas 961
Woodbridge 773
Jacksonville 745
Ashburn 700
Chandler 606
Singapore 580
Fairfield 574
Ann Arbor 503
Wilmington 383
Houston 375
San Jose 364
Boardman 286
Beijing 279
Nanjing 258
Hong Kong 239
Seattle 233
Cambridge 188
Toronto 185
Dearborn 169
Los Angeles 160
The Dalles 143
Düsseldorf 139
Kraków 123
New York 121
Helsinki 119
San Mateo 117
Ho Chi Minh City 102
Columbus 98
Nanchang 98
Johannesburg 95
Seoul 95
Lawrence 93
Princeton 93
Tongling 93
Lauterbourg 90
Istanbul 86
Munich 74
Warsaw 73
Buffalo 72
Ogden 71
Dublin 68
Lachine 67
Moscow 66
London 61
Shanghai 59
Shenyang 59
Camerino 57
Kunming 57
Hanoi 56
Orem 56
Tianjin 55
Guangzhou 50
Santa Clara 46
São Paulo 46
Brussels 45
Venezia 44
Turku 43
Changsha 41
Jiaxing 41
Milan 41
Brno 40
Hebei 37
Chicago 35
Jinan 33
Hangzhou 32
Nürnberg 32
Chennai 31
San Diego 29
Tokyo 27
Philadelphia 26
Venice 26
Zhengzhou 26
Denver 25
Poplar 25
Washington 25
Falls Church 24
Frankfurt am Main 21
Wuhan 20
Boston 19
Orange 19
Redwood City 19
Brooklyn 18
Da Nang 17
Manchester 17
Montreal 17
Taizhou 17
Council Bluffs 16
Fuzhou 16
Amsterdam 15
Leawood 15
Ningbo 15
Stockholm 15
Verona 15
Monmouth Junction 14
Old Bridge 14
Phoenix 14
Atlanta 13
Hefei 13
Ankara 12
Kocaeli 12
Totale 12.470
Salva come PNG Salva come JPEG
Nome #
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 615
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 615
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 551
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 548
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 330
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 327
Hyperphagic effect of novel compounds with high affinity for imidazoline I2 binding sites 302
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 294
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 290
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 267
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 264
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 255
Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms 250
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 246
Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation 241
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 234
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 234
Discovery of Highly Selective Imidazoline Receptor Ligands 221
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 217
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 216
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 216
Structure-activity relationships in 1,4-benzodioxan-related compounds. Investigation on the role of the dehydrodioxane ring on alpha1-adrenoreceptor blocking activity 216
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 209
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 208
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 207
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 206
Novel Imidazoline Compounds as Partial or Full Agonists of D2-Like Dopamine Receptors Inspired by I2-Imidazoline Binding Sites Ligand 2-BFI 206
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 206
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 205
3-Phenyl analogues of 2-[[[2-(2,6-Dimethoxyphenoxyethyllamino]methyl]-1,4-benzodioxan (WB 4101) as highly selective alpha1-adrenoreceptor antagonists1 204
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 203
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 202
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 200
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 199
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 196
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 195
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 194
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 194
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 192
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 191
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 190
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 188
Novel Dopamine Receptor Ligands Bearing Imidazoline Nucleus. 187
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 186
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 186
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 185
Muscarinic Thioligands with Cyclopentane Nucleus 184
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 183
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 179
Chain-lengthened and imidazoline analogues of nicotine 179
Age-related Changes in the Density of Muscarinic Cholinergic M1 and M2 Receptor Subtypes in Pyramidal Neurons or the rat Hippocampus 179
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 178
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 178
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 178
Synthesis and Structure-Activity Relationship Studies in a Series of 2-Substituted 1,3-Dioxolanes Modified at the Cationic Head. 177
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 177
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 172
Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility 171
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 170
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 170
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 169
Rational design of novel I1-imidazoline receptor agonists 168
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 167
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 165
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 164
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 163
From benzodioxane to 1,4-dioxane scaffold in the design of 5-HT1A serotoninergic full agonists from α1-adrenergic antagonists 161
Adrenoceptors as targets in drug discovery: Medicinal chemistry and therapeutical potential 160
Byciclic dioxolanes as potential antimuscarinic agents 160
I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. 160
Alpha 1-adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety 157
Imidazoline nucleus as a biologically versatile scaffold 156
Structure-activity relationship at alpha-adrenergic receptors within a series of imidazoline analogues of cirazoline 156
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 4. Effect of aryl and alkyl Substituents at Position 3 on α-adrenoreceptor blocking activity 155
Effects of allyphenyline on chronic alcohol intoxication model 153
Rational design of new alpha(2)-adrenoreceptor agonists 153
Hybrid molecules from xanomeline and 77-LH-28-1 as potential novel M1 muscarinic agonists 150
Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 6. Role of the Dioxane Unit on Selectivity for Alpha1-Adrenoreceptor Subtypes 142
Binding of Tracizolines to the Imidazoline Receptor. Role of Lipophilicity in Quantitative Structure-Activity Relationship Models. 142
Molecular determinants in the binding of novel 1,4-benzodioxan-related α1D-adrenergic receptor antagonists: a computational study 141
Separation of alpha-adrenergic and imidazoline/guanidinium receptive sites (IGRS) activity in a series of imidazoline analogues of cirazoline 136
Copresence of 1,4-dioxane and quinuclidine nuclei in the design of novel muscarinic antagonists 135
Enantiomers of 6,6-diphenyl-1,4-dioxane derivatives to highlight stereochemical requirements for selective alpha1D-AR and 5- HT1A receptor recognition 135
Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel alpha1-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and alpha1d computational study 130
Structural motives of imidazoline molecules favouring the serotonin 5-HT1A receptor activation 127
Might the observed alpha2A-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations? 126
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 5. Effects of Modification of the side chain on alpha-adrenoreceptor blocking Activity 125
Novel α1-adrenoreceptor antagonists related to openphendioxan: biological evaluation and α1d computational study 120
Synthesis and alpha-blocking activity of some analogues of idazoxan 120
Novel muscarinic antagonists designed on the 1,4-dioxane scaffold 119
Coupling of I-1 Imidazoline Receptors to the cAMP Pathway: Studies with a Highly Selective Ligand, Benazoline 118
Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives 112
Alpha2C-adrenoceptor modulators: a patent review 111
Totale 18.919
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021547 0 0 0 0 0 0 0 0 0 60 322 165
2021/20221.016 88 241 15 74 66 61 25 75 74 118 63 116
2022/20231.528 176 54 66 238 172 204 10 102 284 87 85 50
2023/2024967 156 61 66 28 41 85 34 15 100 37 23 321
2024/20253.009 118 78 250 136 74 156 377 719 246 187 203 465
2025/20264.705 289 353 1.083 667 524 387 692 282 246 182 0 0
Totale 18.919